IE 11 is not supported. For an optimal experience visit our site on another browser.

Immunomedics to Webcast October 15th R&D Day

/ Source: GlobeNewswire

MORRIS PLAINS, N.J., Oct. 8, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it will host a live webcast of its R&D day on Friday, October 15, 2010 from 12:00 p.m. – 2:00 p.m. Eastern Time.

Scheduled R&D day presenters include:

  • Joan T. Merrill, M.D., Member and Chair, Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation OMRF Professor of Medicine, University of Oklahoma Health Sciences Center
  • Allyson J. Ocean, M.D., Medical Oncologist, Attending Physician in Gastrointestinal Oncology, Solid Tumor Division and Assistant Professor of Medicine, New York-Presbyterian Hospital/Weill Cornell Medical Center
  • John P. Leonard, M.D., Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Professor of Medicine, and Clinical Director for Lymphoma and Myeloma, New York-Presbyterian Hospital/Weill Cornell Medical Center

In addition, Immunomedics' senior management team will provide an update on the Company's product pipeline and recent developments.

The webcast will be available via the Investor Relations page on the Company's website at .  A replay of the webcast will be archived on the Company's website through November 14, 2010, and will be available approximately two hours following the live event.

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 150 patents issued in the United States and more than 375 other patents issued worldwide, protects our product candidates and technologies. For additional information on us, please visit our website at . The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Immunomedics, Inc. Dr. Chau Cheng, Director, Investor Relations & Grant Management (973) 605-8200, extension 123